Propanc Biopharma advances PRP toward first-in-human Phase 1b solid tumor trial in Australia

• Propanc Biopharma began finalizing a first-in-human Phase 1b trial protocol for PRP in up to 40 advanced solid-tumor patients.
• Avance Clinical will lead feasibility work across Australian sites ahead of a planned Q4 clinical trial application submission.
• Study design calls for open-label dose escalation and expansion to assess safety, PK/PD, and early antitumor activity, with weekly IV dosing.
• Part A uses a BOIN dose-escalation approach to set up to two recommended doses; Part B adds tumor-specific expansion cohorts.
• Management expects GMP manufacturing to start this year, positioning PRP for initial clinical readouts once enrollment begins.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.